Cardiovascular Effects in Childhood Cancer Survivors Treated with Anthracyclines

Abstract EN

Anthracyclines are commonly used to treat childhood leukemias and lymphomas, as well as other malignancies, leading to a growing population of long-term childhood cancer survivors.

However, their use is limited by cardiotoxicity, increasing survivors' vulnerability to treatment-related complications that can markedly affect their quality of life.

Survivors are more likely to suffer from heart failure, coronary artery disease, and cerebrovascular accidents compared to the general population.

The specific mechanisms of anthracycline cardiotoxicity are complex and remain unclear.

Hence, determining the factors that may increase susceptibility to cardiotoxicity is of great importance, as is monitoring patients during and after treatment.

Additionally, treatment and prevention options, such as limiting cumulative dosage, liposomal anthracyclines, and dexrazoxane, continue to be explored.

Here, we review the cardiovascular complications associated with the use of anthracyclines in treating malignancies in children and discuss methods for preventing, screening, and treating such complications in childhood cancer survivors.